{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T22:58:06Z","timestamp":1774479486543,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s11239-016-1337-4","type":"journal-article","created":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T01:00:47Z","timestamp":1454288447000},"page":"267-271","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Clinical presentations, risk factors, treatment and outcomes in patients with splanchnic vein thrombosis: a single-center experience"],"prefix":"10.1007","volume":"42","author":[{"given":"Kelsey","family":"Klute","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ersilia M.","family":"DeFilippis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelissa","family":"Shillingford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Chapin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria T.","family":"DeSancho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,1]]},"reference":[{"key":"1337_CR1","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.3748\/wjg.v12.i13.2115","volume":"12","author":"M Ogren","year":"2006","unstructured":"Ogren M, Bergqvist D, Bjorck M, Acosta S, Eriksson H, Sternby NH (2006) Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies. World J Gastroenterol 12:2115\u20132119","journal-title":"World J Gastroenterol"},{"key":"1337_CR2","first-page":"99","volume":"40","author":"W Ageno","year":"2014","unstructured":"Ageno W, Riva N, Schulman S et al (2014) Antithrombotic treatment of splanchnic vein thrombosis: results of an international registry. Semin Thromb Hemost 40:99\u2013105","journal-title":"Semin Thromb Hemost"},{"issue":"Suppl 1","key":"1337_CR3","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.thromres.2012.08.259","volume":"130","author":"N Riva","year":"2012","unstructured":"Riva N, Donadini MP, Dentali F, Squizzato A, Ageno W (2012) Clinical approach to splanchnic vein thrombosis: risk factors and treatment. Thromb Res 130(Suppl 1):S1\u2013S3","journal-title":"Thromb Res"},{"key":"1337_CR4","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1097\/MEG.0b013e328357d5d4","volume":"24","author":"L Amitrano","year":"2012","unstructured":"Amitrano L, Guardascione MA, Scaglione M et al (2012) Splanchnic vein thrombosis and variceal rebleeding in patients with cirrhosis. Eur J Gastroenterol Hepatol 24:1381\u20131385","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1337_CR5","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s11239-012-0738-2","volume":"34","author":"I Yonal","year":"2012","unstructured":"Yonal I, Pinarbasi B, Hindilerden F et al (2012) The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis. J Thromb Thrombolysis 34:388\u2013396","journal-title":"J Thromb Thrombolysis"},{"key":"1337_CR6","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/bjh.12461","volume":"162","author":"M Sekhar","year":"2013","unstructured":"Sekhar M, McVinnie K, Burroughs AK (2013) Splanchnic vein thrombosis in myeloproliferative neoplasms. Br J Haematol 162:730\u2013747","journal-title":"Br J Haematol"},{"key":"1337_CR7","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jhep.2009.06.019","volume":"51","author":"J Hoekstra","year":"2009","unstructured":"Hoekstra J, Leebeek FW, Plessier A et al (2009) Paroxysmal nocturnal hemoglobinuria in Budd-Chiari syndrome: findings from a cohort study. J Hepatol 51:696\u2013706","journal-title":"J Hepatol"},{"key":"1337_CR8","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1177\/1076029613511520","volume":"21","author":"D Mutreja","year":"2015","unstructured":"Mutreja D, Kotru M, Sazawal S et al (2015) Hereditary and acquired thrombophilia in splanchnic vein thrombosis: a single-center experience. Clin Appl Thromb Hemost 21:521\u2013526","journal-title":"Clin Appl Thromb Hemost"},{"key":"1337_CR9","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1159\/000360514","volume":"32","author":"M Bianchini","year":"2014","unstructured":"Bianchini M, De Pietri L, Villa E (2014) Coagulopathy in liver diseases: complication or therapy? Dig Dis 32:609\u2013614","journal-title":"Dig Dis"},{"key":"1337_CR10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1365-2141.2012.09249.x","volume":"159","author":"C Tait","year":"2012","unstructured":"Tait C, Baglin T, Watson H et al (2012) Guidelines on the investigation and management of venous thrombosis at unusual sites. Br J Haematol 159:28\u201338","journal-title":"Br J Haematol"},{"key":"1337_CR11","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1182\/blood-2011-09-376517","volume":"120","author":"JH Smalberg","year":"2012","unstructured":"Smalberg JH, Arends LR, Valla DC, Kiladjian JJ, Janssen HL, Leebeek FW (2012) Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood 120:4921\u20134928","journal-title":"Blood"},{"key":"1337_CR12","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1016\/j.thromres.2013.07.014","volume":"132","author":"D Colaizzo","year":"2013","unstructured":"Colaizzo D, Amitrano L, Guardascione MA et al (2013) Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation. Thromb Res 132:e99\u2013e104","journal-title":"Thromb Res"},{"issue":"2 Suppl","key":"1337_CR13","doi-asserted-by":"crossref","first-page":"e419S","DOI":"10.1378\/chest.11-2301","volume":"141","author":"C Kearon","year":"2012","unstructured":"Kearon C, Akl EA, Comerota AJ et al (2012) Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e419S\u2013e494S","journal-title":"Chest"},{"key":"1337_CR14","doi-asserted-by":"publisher","unstructured":"Kearon C, Akl EA, Ornellas J et al. (2016) Antithrombotic Therapy for VTE disease. Chest Guideline. Chest. doi: 10.1016\/j.chest.2015.11.026","DOI":"10.1016\/j.chest.2015.11.026"},{"key":"1337_CR15","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3:692\u2013694","journal-title":"J Thromb Haemost"},{"key":"1337_CR16","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hep.26998","volume":"60","author":"M Martinez","year":"2014","unstructured":"Martinez M, Tandra A, Vuppalanchi R (2014) Treatment of acute portal vein thrombosis by nontraditional anticoagulation. Hepatol 60:425\u2013426","journal-title":"Hepatol"},{"key":"1337_CR17","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1055\/s-0034-1385171","volume":"52","author":"K Lenz","year":"2014","unstructured":"Lenz K, Dieplinger B, Buder R, Piringer P, Rauch M, Voglmayr M (2014) Successful treatment of partial portal vein thrombosis (PVT) with low dose rivaroxaban. Z Gastroenterol 52:1175\u20131177","journal-title":"Z Gastroenterol"},{"key":"1337_CR18","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa1510991","volume":"373","author":"DM Siegal","year":"2015","unstructured":"Siegal DM, Curnutte JT, Connolly SJ et al (2015) Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 373:2413\u20132424","journal-title":"N Engl J Med"},{"key":"1337_CR19","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","volume":"373","author":"CV Pollack Jr","year":"2015","unstructured":"Pollack CV Jr, Reilly PA, Eikelboom J et al (2015) Idarucizumab for Dabigatran Reversal. N Engl J Med 373:511\u2013520","journal-title":"N Engl J Med"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-016-1337-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-016-1337-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-016-1337-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T07:02:11Z","timestamp":1559372531000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-016-1337-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,1]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["1337"],"URL":"https:\/\/doi.org\/10.1007\/s11239-016-1337-4","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,1]]}}}